PITTSBURGH, May 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan PharmaceuticalsInc. has launched Oxycodone Hydrochloride (HCI) Tablets USP, 5 mg, 15 mg and 30 mg, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the generic version of Xanodyne's RoxicodoneŽ, a treatment for moderate to severe
Oxycodone HCI Tablets had U.S. sales of approximately $325 million for the 12 months ending March 31, 2011, according to IMS Health.
Currently, Mylan has 167 ANDAs pending FDA approval representing $100.3 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.
SOURCE Mylan Inc.
Subscribe to our Free Newsletters!
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...
Intermittent fasting is a complete or partial abstinence from food and caloric drinks for a ...View All